BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

...neurodegeneration, CRISPR-based therapeutics, protein degradation, functional genomics in human brain cells and sleep mechanisms and circuits. Selecta’s...
...Biopharma Corp. University of Texas Medical Branch Washington University School of Medicine in St. Louis PureTech Health plc Monash University Selecta Biosciences Inc. University...
BioCentury | Oct 26, 2020
Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...Huntington’s disease. The MMA program, partnered with Selecta Biosciences Inc....
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

...see “Venture to Test how Best to Shake up Benefits Scheme” ). Immune tolerance company Selecta Biosciences Inc....
...Lilly and Co. (NYSE:LLY). BioCentury Staff Pacific Biosciences of California Inc. CMAB Biopharma (Suzhou) Inc. Valo Therapeutics Ltd. Alentis Therapeutics AG Selecta Biosciences Inc. Excision...
BioCentury | Jun 22, 2020
Deals

Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

...responses to AAV vectors, this time with Selecta Biosciences Inc. (NASDAQ:SELB), whose ImmTOR platform produces tolerogenic nanoparticles. Selecta...
...is eligible for preclinical milestone fees; if Sarepta exercises its options to commercial license agreements, Selecta...
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

...Mutation Test as a companion diagnostic for Tazverik. Sarepta taps Selecta tech for gene therapies Selecta Biosciences Inc....
...develop and commercialize gene therapies for Duchenne muscular dystrophy (DMD) and other limb-girdle muscular dystrophies. Selecta...
...an upfront payment and is eligible for preclinical milestone payments. If Sarepta exercises its option, Selecta...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

...Sobi pays $100M up front for Selecta therapy Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights...
...Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta...
...Selecta is also eligible for up to $630 million in milestones plus tiered double-digit royalties. Selecta...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...detection. One example is a collaboration with Selecta Biosciences Inc. (NASDAQ:SELB) to create next-generation gene therapies using Selecta’s...
...shielding viral vectors from the immune system, and is achieving this through collaborations, including with Selecta...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...in an SEC filing (see “Lantheus Enters Therapeutics with Progenics Takeout” ). Immune tolerance company Selecta Biosciences Inc....
...Bio Inc. Arrakis Therapeutics Inc. Coda Biotherapeutics Inc. Kite Pharma Inc. Cerevel Therapeutics LLC Twist Bioscience Corp. Science 37 Inc. Progenics Pharmaceuticals Inc. Selecta Biosciences Inc. Gilead...
BioCentury | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

...the Tesaro Inc. unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Alison Schecter has joined immunology company Selecta Biosciences Inc....
...S.A. (Plan-les-Ouates, Switzerland). Jonathan Block, Associate Editor Disarm Therapeutics Inc. Epizyme Inc. Idera Pharmaceuticals Inc. ImCheck Therapeutics S.A.S. Kaleido Biosciences Inc. Metriopharm AG Selecta Biosciences Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:URGN) 1/23/19 $172.5 $832.7 $747.2 -10% Rexahn Pharmaceuticals Inc. (NASDAQ:REXN) 1/23/19 $8.6 $38.6 $20.7 -46% Selecta Biosciences Inc....
Items per page:
1 - 10 of 76
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

...neurodegeneration, CRISPR-based therapeutics, protein degradation, functional genomics in human brain cells and sleep mechanisms and circuits. Selecta’s...
...Biopharma Corp. University of Texas Medical Branch Washington University School of Medicine in St. Louis PureTech Health plc Monash University Selecta Biosciences Inc. University...
BioCentury | Oct 26, 2020
Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...Huntington’s disease. The MMA program, partnered with Selecta Biosciences Inc....
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

...see “Venture to Test how Best to Shake up Benefits Scheme” ). Immune tolerance company Selecta Biosciences Inc....
...Lilly and Co. (NYSE:LLY). BioCentury Staff Pacific Biosciences of California Inc. CMAB Biopharma (Suzhou) Inc. Valo Therapeutics Ltd. Alentis Therapeutics AG Selecta Biosciences Inc. Excision...
BioCentury | Jun 22, 2020
Deals

Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

...responses to AAV vectors, this time with Selecta Biosciences Inc. (NASDAQ:SELB), whose ImmTOR platform produces tolerogenic nanoparticles. Selecta...
...is eligible for preclinical milestone fees; if Sarepta exercises its options to commercial license agreements, Selecta...
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

...Mutation Test as a companion diagnostic for Tazverik. Sarepta taps Selecta tech for gene therapies Selecta Biosciences Inc....
...develop and commercialize gene therapies for Duchenne muscular dystrophy (DMD) and other limb-girdle muscular dystrophies. Selecta...
...an upfront payment and is eligible for preclinical milestone payments. If Sarepta exercises its option, Selecta...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

...Sobi pays $100M up front for Selecta therapy Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights...
...Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta...
...Selecta is also eligible for up to $630 million in milestones plus tiered double-digit royalties. Selecta...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...detection. One example is a collaboration with Selecta Biosciences Inc. (NASDAQ:SELB) to create next-generation gene therapies using Selecta’s...
...shielding viral vectors from the immune system, and is achieving this through collaborations, including with Selecta...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...in an SEC filing (see “Lantheus Enters Therapeutics with Progenics Takeout” ). Immune tolerance company Selecta Biosciences Inc....
...Bio Inc. Arrakis Therapeutics Inc. Coda Biotherapeutics Inc. Kite Pharma Inc. Cerevel Therapeutics LLC Twist Bioscience Corp. Science 37 Inc. Progenics Pharmaceuticals Inc. Selecta Biosciences Inc. Gilead...
BioCentury | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

...the Tesaro Inc. unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Alison Schecter has joined immunology company Selecta Biosciences Inc....
...S.A. (Plan-les-Ouates, Switzerland). Jonathan Block, Associate Editor Disarm Therapeutics Inc. Epizyme Inc. Idera Pharmaceuticals Inc. ImCheck Therapeutics S.A.S. Kaleido Biosciences Inc. Metriopharm AG Selecta Biosciences Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:URGN) 1/23/19 $172.5 $832.7 $747.2 -10% Rexahn Pharmaceuticals Inc. (NASDAQ:REXN) 1/23/19 $8.6 $38.6 $20.7 -46% Selecta Biosciences Inc....
Items per page:
1 - 10 of 76